SRC is the kinase that phosphorylates ANXA2 at the Tyr23 site [29], and previous in vitro data suggested that the SRC family kinase inhibitor dasatinib has potential therapeutic value in the treatment of ESCC [30, 31]. Here, ANXA2 is linked to esophageal squamous cell carcinoma.